


Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

European Journal of Obstetrics & Gynecology and Reproductive Biology

journal homepage: www.elsevier.com/locate/ejogrb

Corrigendum

Corrigendum to “Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use” [Eur J Obstetr Gynecol Reprod Biol 210 (2017) 22–28]



Kristina Gemzell-Danielsson^a, Dan Apter^b, Sylvia Dermout^c, Thomas Faustmann^d, Kimberly Rosen^e, Thomas Schmelter^d, Martin Merz^{d,*}, Anita Nelson^f

^a Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

^b VL-Medi Clinical Research Center, Helsinki, Finland


^c Gynaecological Centre Dermout & Albicher, Alkmaar, The Netherlands

^d Bayer Pharma AG, Berlin, Germany

^e Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

^f Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, CA, USA

The authors regret the error described as follows: In our manuscript the description of frequent bleeding and infrequent bleeding in the



keys to figure 3 were transposed. Figure 3 as such is correct. Please find below the figure with corrected keys:

DOI of original article: <http://dx.doi.org/10.1016/j.ejogrb.2016.11.022>

* Corresponding author at: Bayer AG, Müllerstr. 178, 13353, Berlin, Germany.

E-mail address: martin.merz@bayer.com (M. Merz).

<http://dx.doi.org/10.1016/j.ejogrb.2018.12.002>

0301-2115/© 2018 Elsevier B.V. All rights reserved.

Fig. 3 Bleeding patterns according to World Health Organization criteria for menstrual bleeding patterns by 90-day RI.

*Defined as no bleeding/spotting throughout the 90-day RI.

†Defined as one or two bleeding/spotting episodes per 90-day RI.

‡Defined as more than five bleeding/spotting episodes per 90-day RI.

§Defined as bleeding/spotting episodes lasting more than 14 days.

RI, reference interval.

The authors would like to apologise for any inconvenience caused.